Reference - Detail
| RRC ID | 39339 |
|---|---|
| Author | Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y. |
| Title | Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. |
| Journal | J Bone Miner Res |
| Abstract |
Osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor (OCIF) is a soluble member of the tumor necrosis factor receptor family of proteins and plays an important role in the negative regulation of osteoclastic bone resorption. Whether OPG/OCIF circulates in human blood and how its level changes under pathological conditions is not known. To address these issues, a panel of monoclonal antibodies was generated against recombinant OPG/OCIF and screened for reactivity with solid-phase monomeric and homodimeric forms of the recombinant protein. Antibodies that showed high affinity for both forms of OPG/OCIF and those that selectively recognized the homodimer were identified, enabling development of two types of sensitive enzyme-linked immunosorbent assay (ELISA): one that detects both forms of OPG/OCIF equally and one specific for the homodimer. Characterization of circulating OPG/OCIF with these ELISAs revealed that the protein exists in human serum mainly in the monomeric form. The serum concentration of OPG/OCIF increased with age in both healthy Japanese men and women, and was significantly higher in postmenopausal women with osteoporosis than in age-matched controls. Within the osteoporotic group, serum OPG/OCIF concentrations were higher in patients with low bone mass. Serum OPG/OCIF concentrations were also significantly increased in those postmenopausal women with a high rate of bone turnover, as determined by increased serum bone-specific alkaline phosphatase and urinary excretion of pyridinoline and deoxypyridinoline. The results suggested that circulating OPG/OCIF levels are regulated by an age-related factor(s) and that the increased serum concentration may reflect a compensative response to enhanced osteoclastic bone resorption and the resultant bone loss rather than a cause of osteoporosis. |
| Volume | 14(4) |
| Pages | 518-27 |
| Published | 1999-4-1 |
| DOI | 10.1359/jbmr.1999.14.4.518 |
| PMID | 10234572 |
| MeSH | Adult Aged Aged, 80 and over Animals Antibodies, Monoclonal Antibody Specificity Bone Density Bone Diseases, Metabolic / blood Bone Diseases, Metabolic / metabolism Case-Control Studies Dimerization Enzyme-Linked Immunosorbent Assay Female Glycoproteins / blood* Glycoproteins / chemistry Glycoproteins / immunology Humans Male Mice Middle Aged Osteoporosis, Postmenopausal / blood* Osteoporosis, Postmenopausal / metabolism Osteoprotegerin Protein Conformation Receptors, Cytoplasmic and Nuclear* Receptors, Tumor Necrosis Factor Recombinant Proteins / chemistry Recombinant Proteins / immunology |
| IF | 5.854 |
| Times Cited | 324 |
| WOS Category | ENDOCRINOLOGY & METABOLISM |
| Altmetric score |
オルトメトリクス指標項目
|
| The most frequently cited source | Patent(IFI CLAIMS) |
| Total number of mentions | 3 |
| Altmetric score changes over past 6months | 0.0 |
| Resource | |
| Human and Animal Cells | ST2(RCB0224) |